Pharmacological differences and switching among anti‐CGRP monoclonal antibodies: A narrative review.

Antibodies targeting either the calcitonin gene–related peptide (CGRP), such as galcanezumab, fremanezumab, and eptinezumab, or the receptor (erenumab) have been approved for the prevention of episodic and chronic migraine. Although widely used and generally effective, a proportion of patients disco...

Full description

Bibliographic Details

Published in:	Headache: The Journal of Head & Face Pain Vol. 65; no. 2; pp. 342 - 353
Main Authors:	Romozzi, Marina, Munafò, Antonio, Burgalassi, Andrea, De Cesaris, Francesco, Vigani, Giulia, Altamura, Claudia, Rivi, Veronica, Guerzoni, Simona, Calabresi, Paolo, Raffaelli, Bianca, Iannone, Luigi Francesco
Format:	review tables/charts Journal Article
Published:	Wiley-Blackwell Feb2025
Online Access:	View this record in EBSCOhost